Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets
Tropical Medicine & International Health · 2026-08 · 31 (8) · 1093-1114
DOI: 10.1111/tmi.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tropical Medicine & International Health, online erschienen am 04.05.2026. Verfasst von Abdullah S Albaqami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Protozoan Proteins, Anti-Bacterial Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Tertiary Education Trust Fund (TETFund) Nigeria, Tertiary Education Trust Fund.
Abstract (Originalsprache)
Background
The emergence of artemisinin resistance in Plasmodium falciparum threatens the sustainability of malaria control programs and underscores the need for new therapeutic strategies. Recently, two proteins, RAD5 (PfRAD5) and WD40‐repeat protein 11 (PfWD11), have been implicated in parasite survival and drug resistance. Their druggability, however, remains underexplored.
Methods
We integrated computational and experimental approaches to assess PfRAD5 and PfWD11 as antimalarial targets. Structural models were retrieved from AlphaFold and aligned with orthologues across Plasmodium species. A library of 216 antibiotics was screened by molecular docking, and molecular dynamics simulations. Top‐ranked compounds were tested against P. falciparum 3D7 cultures in vitro, alone and in combination, and gene expression changes in PfRAD5 and PfWD11 were quantified by qPCR. Docking identified strong binders to PfRAD5 (talampicillin, dicloxacillin, raltegravir) and PfWD11 (cervinomycin A2 monoacetate, eAmSPC 2593, puromycin).
Results
Molecular dynamics confirmed the stability of protein–ligand complexes. In vitro, puromycin exhibited the highest inhibition (85% at 100 μg/mL), while combinations enhanced activity. The triple combination (puromycin + raltegravir + dicloxacillin) achieved complete inhibition, and puromycin + chloroquine exhibited synergistic effects at in a concentration‐dependent manner. qPCR showed consistent downregulation of PfRAD5 and PfWD11 following puromycin‐based treatments, whereas chloroquine alone upregulated PfRAD5 expression. PfRAD5 and PfWD11 represent novel antimalarial targets.
Conclusion
Repurposed antibiotics, particularly puromycin in synergistic regimens, offer a cost‐effective strategy to counteract emerging resistance and accelerate therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
- Department of Microbiology, School of Life Sciences, Federal University of Technology, Minna, Niger State, Nigeria.
ORCID-Profile: Oluwafemi Adebayo Oyewole
Förderung
- Tertiary Education Trust Fund (TETFund) Nigeria
- Tertiary Education Trust Fund
Zitieren
APA
Albaqami, A. S., Oyewole, O. A., & Adam, K. M. (2026). Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets. Tropical Medicine & International Health, 31(8), 1093-1114. https://doi.org/10.1111/tmi.70147
Vancouver
Albaqami AS, Oyewole OA, Adam KM. Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets. Tropical Medicine & International Health. 2026;31(8):1093-1114. doi:10.1111/tmi.70147
BibTeX
@article{Albaqami2026,
author = {Albaqami, Abdullah S and Oyewole, Oluwafemi Adebayo and Adam, Khalid Mohamed},
title = {Repositioning Antibiotics Against Plasmodium falciparum RAD5 and WD11 as Novel Antimalarial Targets},
journal = {Tropical Medicine & International Health},
year = {2026},
volume = {31},
number = {8},
pages = {1093--1114},
doi = {10.1111/tmi.70147}
}
EUVIMED